Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer
In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. The...
Saved in:
| Published in | Journal of personalized medicine Vol. 12; no. 1; p. 65 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
07.01.2022
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. These tools although essential in daily clinical practice for the management of such a heterogeneous disease, which can be cured with a wide spectrum of treatment strategies (i.e., active surveillance, RP and radiation therapy), do not allow the precise distinction of an indolent instead of an aggressive disease. In recent years, several prognostic biomarkers have been tested, combined with the currently available clinicopathologic prognostic tools, in order to improve the decision-making process. In the following article, we reviewed the literature of the last 10 years and gave an overview report on commercially available tissue-based biomarkers and more specifically on mRNA-based gene expression classifiers. To date, these genomic tests have been widely investigated, demonstrating rigorous quality criteria including reproducibility, linearity, analytical accuracy, precision, and a positive impact in the clinical decision-making process. Albeit data published in literature, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence. |
|---|---|
| AbstractList | Simple SummaryIn clinically localized prostate cancer, risk stratification (low-, intermediate- and high-risk) is crucial for the management of such a heterogenic disease, and it is based only on clinicopathologic features (i.e., baseline prostate-specific antigen (PSA), Gleason score and clinical stage of the tumor). New prognostic tools have been developed, mainly based on genomic tissue analysis. The aim of the present overview report is to focus on commercially available tissue-based biomarkers and more specifically on mRNA-based gene expression classifiers: Decipher (GenomeDX Biosciences), Prolaris (Myriad Genetics), and Oncotype Dx (Genomic Health). These new prognostic tests are going to be incorporated in clinicopathologic nomograms to better design the individualized treatment strategy for the cure of localized prostate cancer.AbstractIn localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. These tools although essential in daily clinical practice for the management of such a heterogeneous disease, which can be cured with a wide spectrum of treatment strategies (i.e., active surveillance, RP and radiation therapy), do not allow the precise distinction of an indolent instead of an aggressive disease. In recent years, several prognostic biomarkers have been tested, combined with the currently available clinicopathologic prognostic tools, in order to improve the decision-making process. In the following article, we reviewed the literature of the last 10 years and gave an overview report on commercially available tissue-based biomarkers and more specifically on mRNA-based gene expression classifiers. To date, these genomic tests have been widely investigated, demonstrating rigorous quality criteria including reproducibility, linearity, analytical accuracy, precision, and a positive impact in the clinical decision-making process. Albeit data published in literature, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence. In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced disease, of pelvic lymph node and distant metastasis at diagnosis or the probability of recurrence after radical treatment of the primary tumor. These tools although essential in daily clinical practice for the management of such a heterogeneous disease, which can be cured with a wide spectrum of treatment strategies (i.e., active surveillance, RP and radiation therapy), do not allow the precise distinction of an indolent instead of an aggressive disease. In recent years, several prognostic biomarkers have been tested, combined with the currently available clinicopathologic prognostic tools, in order to improve the decision-making process. In the following article, we reviewed the literature of the last 10 years and gave an overview report on commercially available tissue-based biomarkers and more specifically on mRNA-based gene expression classifiers. To date, these genomic tests have been widely investigated, demonstrating rigorous quality criteria including reproducibility, linearity, analytical accuracy, precision, and a positive impact in the clinical decision-making process. Albeit data published in literature, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence. |
| Author | Alì, Emanuele Saldi, Simonetta Marani, Simona Ingrosso, Gianluca Bellavita, Rita Aristei, Cynthia |
| AuthorAffiliation | 2 Radiation Oncology Section, Perugia General Hospital, 06156 Perugia, Italy; saldisimonetta@gmail.com (S.S.); rita.bellavita@ospedale.perugia.it (R.B.) 1 Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy; emanuele.ali.06@gmail.com (E.A.); maranisimona@libero.it (S.M.); cynthia.aristei@unipg.it (C.A.) |
| AuthorAffiliation_xml | – name: 1 Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy; emanuele.ali.06@gmail.com (E.A.); maranisimona@libero.it (S.M.); cynthia.aristei@unipg.it (C.A.) – name: 2 Radiation Oncology Section, Perugia General Hospital, 06156 Perugia, Italy; saldisimonetta@gmail.com (S.S.); rita.bellavita@ospedale.perugia.it (R.B.) |
| Author_xml | – sequence: 1 givenname: Gianluca orcidid: 0000-0003-4380-6947 surname: Ingrosso fullname: Ingrosso, Gianluca organization: Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy – sequence: 2 givenname: Emanuele orcidid: 0000-0002-6196-5864 surname: Alì fullname: Alì, Emanuele organization: Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy – sequence: 3 givenname: Simona surname: Marani fullname: Marani, Simona organization: Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy – sequence: 4 givenname: Simonetta surname: Saldi fullname: Saldi, Simonetta organization: Radiation Oncology Section, Perugia General Hospital, 06156 Perugia, Italy – sequence: 5 givenname: Rita surname: Bellavita fullname: Bellavita, Rita organization: Radiation Oncology Section, Perugia General Hospital, 06156 Perugia, Italy – sequence: 6 givenname: Cynthia orcidid: 0000-0002-9749-649X surname: Aristei fullname: Aristei, Cynthia organization: Radiation Oncology Section, Department of Medicine and Surgery, Perugia General Hospital, University of Perugia, 06156 Perugia, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35055380$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkd1rFDEUxYNUbK196nsZ8KUgY_M5yb4I7aJVWLAPK_gW7mTutNnOJNtkpqB_vVlay2peTi75cTg35y05CDEgIaeMfhRiQS8225Fxyiht1CtyxKlWtZS8Odi7H5KTnDe0HKM4b-gbcigUVUoYekR-3qR4G2KevKuuMcSx6NrnPGN9BRm76srHEdI9plz5UE13WK0TwjRimKrYV6voYPC_C1iM8gQTVksIDtM78rqHIePJsx6TH18-r5df69X362_Ly1XtJF1MdScNb7Uz0LWMs64HSndTI6Q0zvWgtMKOa9BtA7wHDYppI5F1ElwLxohj8unJdzu3I3au5Eow2G3yJfYvG8Hbf1-Cv7O38dEabdjCyGJw_myQ4sOMebKjzw6HAQLGOVvecM61boQo6Pv_0E2cUyjr7SgmuGJMF-rDE-XKj-SE_UsYRu2uNLtXWqHP9vO_sH8rEn8AOByU8Q |
| CitedBy_id | crossref_primary_10_1038_s41598_022_13332_9 crossref_primary_10_3390_jpm12040585 crossref_primary_10_3390_genes13061019 |
| Cites_doi | 10.1016/j.ijrobp.2014.04.052 10.1111/bju.12554 10.1158/1078-0432.CCR-08-0647 10.1016/j.ijrobp.2013.04.043 10.7326/0003-4819-151-4-200908180-00135 10.1016/S0140-6736(04)16981-X 10.1038/pcan.2013.49 10.1016/j.urology.2016.01.012 10.1200/JCO.2014.59.0026 10.1371/journal.pone.0066855 10.1016/j.eururo.2014.11.030 10.1016/j.eururo.2020.09.042 10.1016/j.eururo.2016.07.008 10.1016/j.eururo.2014.05.004 10.1016/j.eururo.2014.05.039 10.1002/cncr.30665 10.1200/JCO.2012.46.4396 10.1200/JCO.19.02267 10.1038/bjc.2015.223 10.1016/j.juro.2014.02.003 10.1200/JCO.19.02768 10.1186/1471-2164-14-690 10.1016/j.eururo.2017.09.013 10.1016/S1470-2045(10)70295-3 10.1038/s41391-019-0159-9 10.1200/JCO.2005.01.867 10.1016/j.juro.2013.06.017 10.1111/bju.13573 10.1016/j.jmoldx.2015.12.006 10.1016/j.eururo.2011.10.044 10.1016/S0022-5347(17)35410-1 10.1200/JCO.2017.74.2940 10.1016/j.eururo.2015.05.042 10.1200/PO.20.00325 10.1016/j.eururo.2014.11.038 10.1016/j.euf.2017.02.017 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | NPM AAYXX CITATION 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.3390/jpm12010065 |
| DatabaseName | PubMed CrossRef ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2075-4426 |
| ExternalDocumentID | 10_3390_jpm12010065 35055380 |
| Genre | Journal Article Review |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | 53G 5VS 8FE 8FH AADQD AAFWJ ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BBNVY BCNDV BENPR BHPHI CCPQU DIK EMOBN GROUPED_DOAJ GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M48 M7P MODMG M~E NPM OK1 PGMZT PIMPY PROAC RIG RPM AAYXX CITATION ABUWG AZQEC DWQXO GNUQQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c409t-d482b7c8adb121dfa007c8a63448ccfa575ed27a7b6a2fa7a51784e1d4acba883 |
| IEDL.DBID | RPM |
| ISSN | 2075-4426 |
| IngestDate | Tue Sep 17 21:11:50 EDT 2024 Fri Oct 25 01:08:50 EDT 2024 Sat Nov 09 12:23:19 EST 2024 Thu Sep 26 21:06:09 EDT 2024 Sat Sep 28 08:22:16 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | localized prostate cancer tissue-based biomarkers prognostic factors |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c409t-d482b7c8adb121dfa007c8a63448ccfa575ed27a7b6a2fa7a51784e1d4acba883 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-9749-649X 0000-0003-4380-6947 0000-0002-6196-5864 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781984/ |
| PMID | 35055380 |
| PQID | 2621325117 |
| PQPubID | 2032376 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8781984 proquest_miscellaneous_2622277633 proquest_journals_2621325117 crossref_primary_10_3390_jpm12010065 pubmed_primary_35055380 |
| PublicationCentury | 2000 |
| PublicationDate | 20220107 |
| PublicationDateYYYYMMDD | 2022-01-07 |
| PublicationDate_xml | – month: 1 year: 2022 text: 20220107 day: 7 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Journal of personalized medicine |
| PublicationTitleAlternate | J Pers Med |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Canfield (ref_9) 2014; 16 Den (ref_16) 2014; 89 Cooperberg (ref_14) 2015; 67 Lu (ref_36) 2018; 73 Knudsen (ref_21) 2016; 18 ref_12 Karnes (ref_13) 2013; 190 ref_33 Briganti (ref_4) 2012; 61 Stephenson (ref_6) 2005; 23 Lamy (ref_10) 2018; 4 Moschovas (ref_38) 2021; 21 Gore (ref_20) 2017; 123 Wei (ref_30) 2017; 71 Ross (ref_32) 2008; 14 Klein (ref_17) 2016; 90 Tosoian (ref_3) 2017; 119 Den (ref_19) 2015; 33 Cullen (ref_35) 2015; 68 Spratt (ref_22) 2018; 36 Cooperberg (ref_26) 2013; 31 Klein (ref_34) 2014; 66 Lin (ref_39) 2020; 38 Fisher (ref_31) 2004; 364 Ross (ref_15) 2014; 17 Bishoff (ref_24) 2014; 192 Cuzick (ref_27) 2015; 113 Sommariva (ref_29) 2016; 69 Wang (ref_8) 2014; 114 Moher (ref_11) 2009; 151 Eggener (ref_40) 2020; 38 Partin (ref_2) 1993; 150 Brooks (ref_37) 2021; 5 Ross (ref_18) 2016; 69 Canter (ref_28) 2020; 23 ref_5 Freedland (ref_25) 2013; 86 ref_7 Mottet (ref_1) 2021; 79 Cuzick (ref_23) 2011; 12 |
| References_xml | – ident: ref_7 – volume: 89 start-page: 1038 year: 2014 ident: ref_16 article-title: Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2014.04.052 contributor: fullname: Den – volume: 114 start-page: E18 year: 2014 ident: ref_8 article-title: Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer publication-title: BJU Int. doi: 10.1111/bju.12554 contributor: fullname: Wang – volume: 14 start-page: 6602 year: 2008 ident: ref_32 article-title: Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-0647 contributor: fullname: Ross – ident: ref_5 – volume: 86 start-page: 848 year: 2013 ident: ref_25 article-title: Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2013.04.043 contributor: fullname: Freedland – volume: 151 start-page: 264 year: 2009 ident: ref_11 article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-151-4-200908180-00135 contributor: fullname: Moher – volume: 364 start-page: 858 year: 2004 ident: ref_31 article-title: National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials publication-title: Lancet doi: 10.1016/S0140-6736(04)16981-X contributor: fullname: Fisher – volume: 17 start-page: 64 year: 2014 ident: ref_15 article-title: A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/pcan.2013.49 contributor: fullname: Ross – volume: 90 start-page: 148 year: 2016 ident: ref_17 article-title: Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk publication-title: Urology doi: 10.1016/j.urology.2016.01.012 contributor: fullname: Klein – volume: 33 start-page: 944 year: 2015 ident: ref_19 article-title: Genomic classifier identifies men with adverse pathology after RP who benefit from adjuvant radiation therapy publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.0026 contributor: fullname: Den – ident: ref_12 doi: 10.1371/journal.pone.0066855 – volume: 68 start-page: 123 year: 2015 ident: ref_35 article-title: A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After RP and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.11.030 contributor: fullname: Cullen – volume: 79 start-page: 243 year: 2021 ident: ref_1 article-title: Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent publication-title: Eur. Urol. doi: 10.1016/j.eururo.2020.09.042 contributor: fullname: Mottet – volume: 71 start-page: 183 year: 2017 ident: ref_30 article-title: Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.07.008 contributor: fullname: Wei – volume: 66 start-page: 550 year: 2014 ident: ref_34 article-title: A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.05.004 contributor: fullname: Klein – volume: 67 start-page: 326 year: 2015 ident: ref_14 article-title: Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.05.039 contributor: fullname: Cooperberg – volume: 123 start-page: 2850 year: 2017 ident: ref_20 article-title: Decipher test impacts decision making among patients considering adjuvant and salvage treatment after RP: Interim results from the Multicenter Prospective PRO-IMPACT study publication-title: Cancer doi: 10.1002/cncr.30665 contributor: fullname: Gore – volume: 31 start-page: 1428 year: 2013 ident: ref_26 article-title: Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.46.4396 contributor: fullname: Cooperberg – volume: 38 start-page: 1549 year: 2020 ident: ref_39 article-title: 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.02267 contributor: fullname: Lin – volume: 113 start-page: 382 year: 2015 ident: ref_27 article-title: Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort publication-title: Br. J. Cancer doi: 10.1038/bjc.2015.223 contributor: fullname: Cuzick – volume: 192 start-page: 409 year: 2014 ident: ref_24 article-title: Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy publication-title: J. Urol. doi: 10.1016/j.juro.2014.02.003 contributor: fullname: Bishoff – volume: 38 start-page: 1474 year: 2020 ident: ref_40 article-title: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.02768 contributor: fullname: Eggener – volume: 21 start-page: S2405 year: 2021 ident: ref_38 article-title: Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After RP publication-title: Eur. Urol. Focus contributor: fullname: Moschovas – ident: ref_33 doi: 10.1186/1471-2164-14-690 – volume: 73 start-page: 129 year: 2018 ident: ref_36 article-title: A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease publication-title: Eur. Urol. doi: 10.1016/j.eururo.2017.09.013 contributor: fullname: Lu – volume: 12 start-page: 245 year: 2011 ident: ref_23 article-title: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70295-3 contributor: fullname: Cuzick – volume: 23 start-page: 102 year: 2020 ident: ref_28 article-title: Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/s41391-019-0159-9 contributor: fullname: Canter – volume: 16 start-page: 172 year: 2014 ident: ref_9 article-title: A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer publication-title: Rev. Urol. contributor: fullname: Canfield – volume: 23 start-page: 7005 year: 2005 ident: ref_6 article-title: Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After RP publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.01.867 contributor: fullname: Stephenson – volume: 190 start-page: 2047 year: 2013 ident: ref_13 article-title: Validation of a genomic classifier that predicts metastasis following RP in an at risk patient population publication-title: J. Urol. doi: 10.1016/j.juro.2013.06.017 contributor: fullname: Karnes – volume: 119 start-page: 676 year: 2017 ident: ref_3 article-title: Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era publication-title: BJU Int. doi: 10.1111/bju.13573 contributor: fullname: Tosoian – volume: 18 start-page: 395 year: 2016 ident: ref_21 article-title: Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens publication-title: J. Mol. Diagn doi: 10.1016/j.jmoldx.2015.12.006 contributor: fullname: Knudsen – volume: 61 start-page: 480 year: 2012 ident: ref_4 article-title: Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: The essential importance of percentage of positive cores publication-title: Eur. Urol. doi: 10.1016/j.eururo.2011.10.044 contributor: fullname: Briganti – volume: 150 start-page: 110 year: 1993 ident: ref_2 article-title: Clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer publication-title: J. Urol. doi: 10.1016/S0022-5347(17)35410-1 contributor: fullname: Partin – volume: 36 start-page: 581 year: 2018 ident: ref_22 article-title: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2017.74.2940 contributor: fullname: Spratt – volume: 69 start-page: 157 year: 2016 ident: ref_18 article-title: Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men publication-title: Eur. Urol. doi: 10.1016/j.eururo.2015.05.042 contributor: fullname: Ross – volume: 5 start-page: 442 year: 2021 ident: ref_37 article-title: GPS Assay Association with Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality publication-title: JCO Precis. Oncol. doi: 10.1200/PO.20.00325 contributor: fullname: Brooks – volume: 69 start-page: 107 year: 2016 ident: ref_29 article-title: Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.11.038 contributor: fullname: Sommariva – volume: 4 start-page: 790 year: 2018 ident: ref_10 article-title: Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review publication-title: Eur. Urol. Focus doi: 10.1016/j.euf.2017.02.017 contributor: fullname: Lamy |
| SSID | ssj0000852260 |
| Score | 2.2391503 |
| SecondaryResourceType | review_article |
| Snippet | In localized prostate cancer clinicopathologic variables have been used to develop prognostic nomograms quantifying the probability of locally advanced... Simple SummaryIn clinically localized prostate cancer, risk stratification (low-, intermediate- and high-risk) is crucial for the management of such a... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 65 |
| SubjectTerms | Biomarkers Biopsy Cancer therapies Cell cycle Clinical medicine Decision making Gene expression Genomic analysis Lymph nodes Metastases Metastasis Multivariate analysis Precision medicine Prostate cancer Prostate-specific antigen Radiation therapy Review Risk assessment Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED90A_FF_LZ-EWGvYW2SNvFJnDhF3Biywd5K2rRYwXZu88W_3kvXzk3BxzaBlrvL3e8-A9AK4jjSRkaUc8-ngumIau1yKoKE-66WxqS2UbjXDx5H4mnsj6uA26wqq6x1YqmoTRHbGHmbBQwdJ4QH8mbyQe2tUTa7Wl2hsQlNhp6C24Bm574_eFlGWRBQIL5wF415HP379tvk3bMZYNeak1VT9Adf_i6TXLE73V3YqQAjuV1weA82knwftnpVSvwAxoNpYYvlcJk8JGWTMRmW1KQdtFCGdLLi3dbgTGckywniPTKsi8tJkZJna8yyL9w4sA0gCD3JnZWE6SGMuvfDu0daXZdAY3TS5tQIxSIZK20ij3km1Wj-8Sng6IHFcaoRmCWGSS2jQLNUS-17UonEM0Ijv5TiR9DIizw5AcL8yL1mvgrwtUCMdi2kTFOjET4y7XHlQKumXDhZTMUI0ZuwBA5XCOzAeU3VsDoas_CHkQ5cLZdRqG2mQudJ8VnuYUyi6uMOHC-YsPwOipCPWtp1QK6xZ7nBDsxeX8mz13JwtpKIf5Q4_f-3zmCb2R4HG2eR59CYTz-TC0Qe8-iyEq9vNGjbkw priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1dS8MwFL3MCcMX8dvqlAh7ja5p2sQHERV1iJM9bLC3kjYtTrSd3QT113vTj7FNfWyTtuHeNOec5N4EoOWFYaC0CKjj2C7lTAVUqbZDuRc5blsJrWOTKNx98joD_jB0hzWoDuMsDTj5U9qZ86QG2evp5_vXJf7wF0ZxomQ_exm_2WZRF9F0BVYZR4luYvhKnv9SBGMhzTDzLQwhknKEpSJXb_n5NWhgE10cBdqLQPWLfS4HUc6h0t0GrJd0klwV_t-EWpRsQaNbLphvw7CXpSaUDovJfZSnIJN-bmt6jfilyfUofTMROtmEjBKCbJD0q9Bzksbk0UDd6Bsr9kx6CBJTcmP6SbYDg7vb_k2Hlocp0BAl3JRqLlkgQql0YDNbxwrJAV55DuqzMIwV0rZIM6FE4CkWK6FcW0ge2Zor9KaUzi7UkzSJ9oEwN2ifM1d6eJsjgzvnQsSxVkgumbIdaUGrspw_LvbM8FFrGFv7c7a2oFlZ1a_87jOPoT5GFigsOJkVY5c36xgqidKPvA5jAgdGx4K9wgmz71Tes0AsuGdWwWynvViSjJ7zbbWlQHYk-cG_7zyENWaSH8wEjGhCfZp9REdISabBcd7dfgBabt4o priority: 102 providerName: Scholars Portal |
| Title | Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35055380 https://www.proquest.com/docview/2621325117 https://search.proquest.com/docview/2622277633 https://pubmed.ncbi.nlm.nih.gov/PMC8781984 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFD64CeKLeLc6RwRf69okbeKjG14QJ0Mm7K0kTYsV1445X_z1nvQyNn3zpdAmpeGck37fab6TAlyGcayVEdplzA9cTpV2lfKYy8OEBZ4SxqS2UHj4HD688sdJMNmAoKmFKUX7sc6u8o_pVZ69ldrK2TTuNTqx3mg4kAJxTPJeC1oYoCsp-nslvEJK4VW1eAxT-t77bOrbRV9E223YwiEEOMu9dSD6wy5_iyRXUOduF3ZqukhuqmHtwUaS78PWsF4QP4DJaF5YqRw2k_ukLDEm49KWbh_xyZB-VkytAmf-SbKcINsj40ZaToqUPFkoy76x48iWfyDxJAMbB_NDeL27HQ8e3PpnCW6MKdrCNVxSLWKpjPapb1KF4I9nIcP8K45ThbQsMVQooUNFUyVU4AvJE99whd6Skh1BOy_y5AQIDbR3TQMZ4mWODO2aC5GmRiF5pMpn0oHLxnLRrNoTI8Jcwto6WrG1A53GqlE9MT4jGlLMf5HlCQculs0Y0nadQuVJ8VX2oVTgi485cFw5YfmcxnsOiDX3LDvY7bLXWzCKym2z66g5_fedZ7BNbfGD_QAjOtBezL-Sc6QkC92Fzf7t8-ilC637iY_HIZfdMix_AEeY5sA |
| link.rule.ids | 230,315,730,783,787,888,2228,21400,24330,27936,27937,33756,33757,43817,53804,53806,74636 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED9tRWK8TIyvZYPNSLxaJLYTmydEEV23tVWFWqlvkRMnopOalH688Ndzl6ZdAYnHxJYS3Z3vfvdpgIsoTRPrdMKlDEKuhE24tb7kKspk6FvtXE6Nwt1e1B6qP6NwVAfc5nVZ5VonVoralSnFyC9FJNBxQnigr6ePnG6NouxqfYXGR9ihUVXofO0073r9-02UBQEF4gt_1Zgn0b-__DedBJQB9smcbJuiN_jydZnklt1p7cPnGjCymxWHv8CHrDiA3W6dEj-EUX9WUrEcLrNfWdVkzAYVNXkTLZRjzXE5oRqc2ZyNC4Z4jw3WxeWszFmHjNn4CTf2qQEEoSe7JUmYHcGwdTe4bfP6ugSeopO24E4ZkejUWJcEInC5RfOPT5FEDyxNc4vALHNCW51EVuRW2zDQRmWBUxb5ZYw8hkZRFtlXYCJM_CsRmghfK8RoV0rrPHcW4aOwgTQeXKwpF09XUzFi9CaIwPEWgT04XVM1ro_GPP7PSA_ON8so1JSpsEVWLqs9QmhUfdKDkxUTNt9BEQpRS_se6Bfs2WyggdkvV4rxQzU422jEP0Z9e_-3fsKn9qDbiTu_e3-_w56gfgeKuehTaCxmy-wMUcgi-VGL2jPGm96N |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1RT9swED5tRUJ7QYwBCzDwJF6tJrYTmydEgcI2qKqpSH2LnDgRnURS2vLCr-cudbsCEo-pLTW6u9x95_vuDHCc5Hlmnc64lFHMlbAZtzaUXCWFjEOrnSupUfi2l1zfqd_DeOj5T1NPq1z4xMZRuzqnM_K2SAQmTggPdLv0tIj-Rfd0_MjpBimqtPrrND7DmqYpWC1Y61z2-n-XJy4ILhBrhPMmPYm5fvvf-CGianBIoWU1LL3Dmm8pkysxqLsJGx48srO5tr_Cp6LagvVbXx7_BsP-pCbiHC6zq6JpOGaDRrK8g9HKsc6ofiA-zmTKRhVD7McGC6I5q0t2Q4Ft9Iwb-9QMgjCUnZNVTLbhrns5OL_m_uoEnmPCNuNOGZHp3FiXRSJypUUogE-JxGwsz0uLIK1wQludJVaUVts40kYVkVMWdWeM3IFWVVfFd2AizsITEZsEf1aI106U1mXpLEJJYSNpAjheSC4dzydkpJhZkIDTFQEHcLCQauo_k2n6X6kB_Fwuo4FT1cJWRf3U7BFCoxuUAezOlbD8HzSnGD12GIB-pZ7lBhqe_XqlGt03Q7SNRixk1N7Hr3UE62hl6c2v3p99-CKo9YGOX_QBtGaTp-IHApJZdugt7QX2PeLB |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Genomic+Tissue-Based+Biomarkers+in+the+Treatment+of+Localized+Prostate+Cancer&rft.jtitle=Journal+of+personalized+medicine&rft.au=Ingrosso%2C+Gianluca&rft.au=Al%C3%AC%2C+Emanuele&rft.au=Marani%2C+Simona&rft.au=Saldi%2C+Simonetta&rft.date=2022-01-07&rft.issn=2075-4426&rft.eissn=2075-4426&rft.volume=12&rft.issue=1&rft_id=info:doi/10.3390%2Fjpm12010065&rft_id=info%3Apmid%2F35055380&rft.externalDocID=35055380 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2075-4426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2075-4426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2075-4426&client=summon |